Bronchiolitis Surge: Adults Now at Risk as Virus Spreads Beyond Infants
Paris, France – A resurgence of bronchiolitis, traditionally a concern for infants, is now impacting adults, prompting health authorities to expand vaccination recommendations and reinforce preventative measures. While newborns have been the primary focus of protection, recent data reveals a broader vulnerability, especially among the elderly.
Bronchiolitis, a common respiratory infection, is caused by the Respiratory Syncytial Virus (RSV). historically, it posed the greatest threat to babies, but this season’s viral circulation is affecting a wider age range. The High Authority for Health (HAS) reports that the new preventative antibody, Beyfortus, reduces severe RSV infections in newborns by 81.8% in the first three months of life by allowing the mother to transmit her antibodies to the fetus. The HAS approved vaccination for those 75 and older, and 65-74 year olds at risk, with arexvy (GSK) and Abrysvo (Pfizer) now available (HAS, 2024).This expanded approach reflects a growing understanding of RSV’s impact across all age groups.
Prevention remains crucial. Simple barrier gestures – hand washing, avoiding kissing infants when sick, ventilating rooms, and mask-wearing when necessary – are effective in curbing transmission. These measures, often overlooked since the COVID-19 pandemic, are vital for protecting both the young and the elderly. Seniors are advised to stay warm, avoid crowded spaces when symptomatic, and seek early medical attention at the first sign of a cough.
beyfortus, a monoclonal antibody, received European approval in fall 2022 and became available in France in September 2023, with initial injections administered to newborns from February 6, 2023. The rollout began with limited public awareness, marking a notable, yet initially quiet, step forward in preventative medicine.
